Needham Reiterates Buy on Taysha Gene Therapies, Maintains $8 Price Target

Benzinga · 06/10 10:40
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $8 price target.